Alnylam Pharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($1.17) Per Share (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at Zacks Research boosted their Q1 2024 EPS estimates for Alnylam Pharmaceuticals in a report released on Wednesday, April 10th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of ($1.17) per share for the quarter, up from their previous estimate of ($1.43). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($4.61) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.05) EPS, Q4 2024 earnings at ($0.88) EPS, FY2024 earnings at ($4.49) EPS, Q1 2025 earnings at ($0.57) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.98) EPS, Q1 2026 earnings at $0.32 EPS and FY2026 earnings at $3.89 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.68) EPS.

ALNY has been the topic of several other reports. Wells Fargo & Company lowered their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a research report on Friday, February 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Needham & Company LLC reiterated a “buy” rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Nine analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $148.50 on Friday. Alnylam Pharmaceuticals has a 1 year low of $143.52 and a 1 year high of $218.88. The firm has a market cap of $18.70 billion, a price-to-earnings ratio of -41.71 and a beta of 0.39. The firm’s 50 day moving average price is $153.99 and its two-hundred day moving average price is $167.85.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Alnylam Pharmaceuticals by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after acquiring an additional 287,064 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $52,000. Eventide Asset Management LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $16,653,000. Public Employees Retirement System of Ohio lifted its position in Alnylam Pharmaceuticals by 1.4% during the 4th quarter. Public Employees Retirement System of Ohio now owns 55,417 shares of the biopharmaceutical company’s stock worth $10,607,000 after acquiring an additional 747 shares during the last quarter. Finally, Employees Retirement System of Texas acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth $720,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.